Cargando…

Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study

Objective To evaluate the use of special expedited development and review pathways at the US Food and Drug Administration over the past two decades. Design Cohort study. Setting FDA approved novel therapeutics between 1987 and 2014. Population Publicly available sources provided each drug’s year of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kesselheim, Aaron S, Wang, Bo, Franklin, Jessica M, Darrow, Jonathan J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4580726/ https://www.ncbi.nlm.nih.gov/pubmed/26400751 http://dx.doi.org/10.1136/bmj.h4633

Ejemplares similares

Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study
por: Hwang, Thomas J, et al.
Publicado: (2020)

Use of Expedited Regulatory Programs and Clinical Development Times for FDA-Approved Novel Therapeutics
por: Wong, Alissa K., et al.
Publicado: (2023)

FDA expedited approval and implications for rational formulary and health plan design
por: Ferries, Erin A, et al.
Publicado: (2021)

Evidence at time of regulatory approval and cost of new antibiotics in 2016-19: cohort study of FDA approved drugs
por: Mitra-Majumdar, Mayookha, et al.
Publicado: (2022)

Physicians’ Trust in the FDA’s Use of Product-Specific Pathways for Generic Drug Approval
por: Kesselheim, Aaron S., et al.
Publicado: (2016)

Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study
por: Mostaghim, Sana R, et al.
Publicado: (2017)

Changing FDA Approval Standards: Ethical Implications for Patient Consent
por: Darrow, Jonathan J., et al.
Publicado: (2021)

Did FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children?: A Time-Trend Analysis
por: Wang, Bo, et al.
Publicado: (2016)

The FDA’s New Guideline “Generally Accepted Scientific Knowledge” (GASK): An Opportunity to Expedite the Approval of Biosimilars
por: Niazi, Sarfaraz K.
Publicado: (2023)

Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs
por: Gyawali, Bishal, et al.
Publicado: (2020)

Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia
por: Hwang, Thomas J., et al.
Publicado: (2022)

The Potential Benefit of Expedited Development and Approval Programs in Precision Medicine
por: Kantor, Ariel, et al.
Publicado: (2021)

Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986–2019
por: Olsen, Anders, et al.
Publicado: (2023)

Innovation and trends in the development and approval of antiviral medicines: 1987–2017 and beyond
por: Chaudhuri, Shuvam, et al.
Publicado: (2018)

Comparison of rates of safety issues and reporting of trial outcomes for medical devices approved in the European Union and United States: cohort study
por: Hwang, Thomas J, et al.
Publicado: (2016)

Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014
por: Hatswell, Anthony J, et al.
Publicado: (2016)

Few new drugs deserve expedited regulatory treatment
por: Darrow, Jonathan J
Publicado: (2021)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

Approved SPS experiments: January 1987
por: CERN. Geneva. SPS Experiments Committee
Publicado: (1987)

Post‐Marketing Requirements for Cancer Drugs Approved by the European Medicines Agency, 2004–2014
por: Cherla, Avi, et al.
Publicado: (2022)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

The FDA's Final Rule on Expedited Safety Reporting: Statistical Considerations
por: Wittes, Janet, et al.
Publicado: (2015)

Elderly suicide trends in the context of transforming China, 1987–2014
por: Zhong, Bao-Liang, et al.
Publicado: (2016)

Commentary: Expedited Regulatory Review of Low-Value Drugs
por: Darrow, Jonathan J., et al.
Publicado: (2020)

Trends in FDA drug approvals over last 2 decades: An observational study
por: Batta, Angelika, et al.
Publicado: (2020)

SUN-249 Growth Hormone Utilization By US Youth: Trends as Insurance Pushes Back after FDA-Approved Expansion
por: Grimberg, Adda, et al.
Publicado: (2019)

Expedited approval system for regenerative medicine products – Is it unusual?
por: Yano, Kazuo, et al.
Publicado: (2016)

Expedited regulatory product approval in the time of COVID-19
por: Novack, Gary D.
Publicado: (2022)

Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

ICP Materials Trends in Corrosion, Soiling and Air Pollution (1987–2014)
por: Tidblad, Johan, et al.
Publicado: (2017)

Utilization Rate of Healthcare Service of the Elderly with Disabilities — China, 1987−2014
por: Guo, Chao, et al.
Publicado: (2020)

Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs
por: Tompa, Dharma Rao, et al.
Publicado: (2021)

Trends and Perspectives of Biological Drug Approvals by the FDA: A Review from 2015 to 2021
por: Martins, Alexander C., et al.
Publicado: (2022)

FDA Coronavirus Treatment Acceleration Program: approved drugs and those in clinical trials
por: Nainwal, Lalit Mohan, et al.
Publicado: (2022)

Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021
por: Beakes-Read, Ginny, et al.
Publicado: (2022)

Incentivizing Antibiotic Development: Why Isn’t the Generating Antibiotic Incentives Now (GAIN) Act Working?
por: Darrow, Jonathan J, et al.
Publicado: (2020)

Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020
por: Mitra-Majumdar, Mayookha, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_iebco2mvbfhf9fsg7o29ecmr06